This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should You Buy Penumbra (PEN) Ahead of Earnings?
by Zacks Equity Research
Penumbra (PEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Si-Bone (SIBN) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Si-Bone (SIBN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DaVita (DVA) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
High labor costs, along with inflationary pressures, are likely to have weighed on DaVita's (DVA) fourth-quarter top line.
Penumbra (PEN) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Penumbra (PEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top Stock Picks for Week of February 13, 2023
by Panel Of Zacks Experts
A Medical and Financial Stock Worth a Look.
AMN Healthcare (AMN) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
AMN Healthcare's (AMN) fourth-quarter results are likely to reflect soft demand across the majority of its segments.
What's in Store for West Pharmaceutical (WST) in Q4 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) fourth-quarter results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements are likely to hurt the top and the bottom lines.
Insulet (PODD) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
In Drug Delivery, Insulet (PODD) is expected to have faced higher manufacturing costs in Q4.
Ecolab (ECL) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Ecolab's (ECL) fourth-quarter results are likely to reflect continued strength in its Global Industrial segment.
PerkinElmer (PKI) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
PerkinElmer's (PKI) fourth-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for discovery business, and informatics franchise.
What's in the Cards for Medtronic (MDT) in Q3 Earnings?
by Zacks Equity Research
Severe currency headwinds are expected to have affected Medtronic's (MDT) profitability in fiscal Q3.
Catalent (CTLT) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Catalent's (CTLT) Q2 results are likely to have been driven by robust segmental performances.
4 Low-Beta Stocks to Buy to Sail Through the Volatile Market
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Penumbra (PEN), Patria Investments (PAX), Lamb Weston (LW) and BJ's Wholesale (BJ) are poised to gain.
Should iShares Morningstar SmallCap ETF (ISCB) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for ISCB
4 Low-Beta Stocks to Buy to Sail Through the Volatile Market
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Penumbra (PEN), Patria Investments (PAX), Lamb Weston (LW) and Conagra Brands (CAG) are poised to gain.
Top Stock Picks for Week of January 9, 2023
by Panel Of Zacks Experts
A Food Company That's Attracting Investor Attention and a Medical Device Company Topping Q3 Earnings and Revenue Estimates.
Should iShares Morningstar SmallCap Growth ETF (ISCG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for ISCG
Penumbra (PEN) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Penumbra (PEN) delivered earnings and revenue surprises of 200% and 0.60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Penumbra (PEN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Penumbra (PEN) Surges 6.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Penumbra (PEN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Penumbra (PEN) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Penumbra (PEN) delivered earnings and revenue surprises of 114.29% and 1.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Idexx Laboratories (IDXX) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 1.30% and 0.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Ekso Bionics (EKSO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ekso Bionics (EKSO) delivered earnings and revenue surprises of 4.17% and 0.72%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Penumbra (PEN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Penumbra (PEN) Surges 3.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
Penumbra (PEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.